

VRBPAC VOTING QUESTION # 1

Are the available data adequate to support the safety of AREXVY (RSVPreF3+AS01_E) when administered to individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV?

Please vote “Yes” or “No”

VRBPAC VOTING QUESTION # 2

Are the available data adequate to support the effectiveness of AREXVY (RSVPreF3+AS01E) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older?

Please vote “Yes” or “No”